Eleven-year management of prostate cancer patients on active surveillance: what have we learned?
Marenghi C, Alvisi MF, Palorini F, Avuzzi B, Badenchini F, Bedini N, Bellardita L, Biasoni D, Bosetti D, Casale A, Catanzaro M, Colecchia M, De Luca L, Donegani S, Dordoni P, Lanocita R, Maffezzini M, Magnani T, Menichetti J, Messina A, Morlino S, Paolini B, Rancati T, Stagni S, Tesone A, Torelli T, Tulli Baldoin E, Vaiani M, Villa S, Villa S, Zaffaroni N, Nicolai N, Salvioni R, Valdagni R. Tumori. 2017 Jun 14:0.
doi: 10.5301/tj.5000649

2017

microRNAs as players and signals in the metastatic cascade: Implications for the development of novel anti-metastatic therapies
Gandellini P, Doldi V, Zaffaroni N
Semin Cancer Biol. 2017 Jun;44:132-140. doi: 10.1016/j.semcancer.2017.03.005.
Epub 2017 Mar 23.

2017

miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis
El Bezawy R, Cominetti D, Fenderico N, Zuco V, Beretta GL, Dugo M, Arrighetti N, Stucchi C, Rancati T, Valdagni R, Zaffaroni N, Gandellini P
Cancer Lett. 2017 Jun 1;395:53-62. doi: 10.1016/j.canlet.2017.02.033. Epub 2017 Mar 6.

2017

MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs.
Pennati M, Folini M, Gandellini P, Zaffaroni N.
Curr Drug Targets. 2016;17(3):257-65. Review.

2016

Dissecting the role of microRNAs in prostate cancer metastasis: implications for the design of novel therapeutic approaches. 
Doldi V, Pennati M, Forte B, Gandellini P, Zaffaroni N
Cell Mol Life Sci. 2016 Jul;73(13):2531-42. doi: 10.1007/s00018-016-2176-3. Epub 2016 Mar 12.

2016

Targeting microRNAs to withstand cancer metastasis.
Profumo V, Doldi V, Gandellini P, Zaffaroni N.
Methods Mol Biol. 2015;1218:415-37. doi: 10.1007/978-1-4939-1538-5_25.

2015

Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation.
Doldi V, Callari M, Giannoni E, D'Aiuto F, Maffezzini M, Valdagni R, Chiarugi P, Gandellini P, Zaffaroni N
Oncotarget. 2015 Oct 13;6(31):31441-60. doi: 10.18632/oncotarget.5056.

2015

Senescent stroma promotes prostate cancer progression: The role of miR-210.
Taddei ML, Cavallini L, Comito G, Giannoni E, Folini M, Marini A, Gandellini P, Morandi A, Pintus G, Raspollini MR, Zaffaroni N, Chiarugi P
Mol Oncol. 2014 Dec;8(8):1729-46. doi: 10.1016/j.molonc.2014.07.009.
Epub 2014 Jul 21.

2014

miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells.
Pennati M, Lopergolo A, Profumo V, De Cesare M, Sbarra S, Valdagni R, Zaffaroni N, Gandellini P,
Folini M
Biochem Pharmacol. 2014 Feb 15;87(4):579-97. doi: 10.1016/j.bcp.2013.12.009.
Epub 2013 Dec 24.

2014

miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts.
Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Piovan C, Valdagni R, Pierotti MA, Zaffaroni N, Chiarugi P
Antioxid Redox Signal.
2014 Mar 1;20(7):1045-59.
doi: 10.1089/ars.2013.5292.
Epub 2013 Sep 17.

2014

MicroRNAs: cobblestones on the road to cancer metastasis.
Profumo V, Gandellini P.
Crit Rev Oncog.
2013;18(4):341-55.

2013

MicroRNA-mediated control of prostate cancer metastasis: implications for the identification of novel biomarkers and therapeutic targets.
Fenderico N, Casamichele A, Profumo V, Zaffaroni N,
Gandellini P.  
Curr Med Chem. 2013;20(12):1566-84.

2013

Copyright © 2017 INT

Fondazione IRCCS Istituto Nazionale dei Tumori

Tutti i diritti sono riservati

website by Studio Luvié

Copyright © 2017 INT

Fondazione IRCCS Istituto Nazionale dei Tumori

Tutti i diritti sono riservati

website by Studio Luvié

Progetto finanziato con

il contributo Airc 5x1000

Copyright © 2017 INT

Fondazione IRCCS Istituto Nazionale dei Tumori

Tutti i diritti sono riservati

website by Studio Luvié